Effects of oral casokefamide on plasma levels, tolerance, and intestinal transit in man

Peptides

Volumn 21, Issue 3, 2000, Pages 439-442

  Schulte Frohlinde, Ewert ^a   Reindl, Wolfgang ^a   Bierling, Daniela ^a   Lersch, Christian ^a   Brantl, Victor ^b   Teschemacher, Hansjörg ^c   Schusdziarra, Volker ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Siegfried Switzerland   (Switzerland)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Casomorphin; Casokefamide; Human study; Motility; Opioid peptides; Plasma levels

Indexed keywords

BETA CASOMORPHINE; TYROSYL DEXTRO ALANYLPHENYLALANYL DEXTRO ALANYLTYROSINAMIDE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDORPHINS; GASTROINTESTINAL TRANSIT; HUMANS; IODINE RADIOISOTOPES; LACTULOSE; MALE; PLACEBOS;

EID: 0033996761     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00166-2     Document Type: Article

References (15)

1. Basilisco G., Bozzani A., Camboni G., et al. Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test. Gut. 26:1985;700-703.
2. Brantl V. Novel opioid peptides derived from human β-casein. Eur J Pharmacol. 106:1984;213-214.
3. Brantl V., Picone D., Amodeo P., Temussi P.A. Solution structure of casokefamide. Biochem Biophys Res Comm. 191:1993;853-859.
4. Brantl V., Teschemacher H. A material with opioid activity in bovine milk and milk products. Naunyn-Schmiedeberg's Arch Pharmacol. 303:1979;301-304.
5. Brantl V., Teschemacher H., Henschen H., Lottspeich F. Novel opioid peptides derived from casein (β-casomorphins). Hoppe-Seyler's Z Physiol Chem. 360:1979;1211-1216.
6. Daniel H., Wessendorf A., Vohwinkel M., Brantl V. Effects of D-Ala 2,4, Tyr 5-β-casomorphin-5-amide on gastrointestinal functions. Nyberg F., Brantl V. β-casomorphins and related peptides. 1990;95-104 Fyris-Tryck AB, Uppsala, Sweden.
7. Erll G., Hahn A., Brantl V., Daniel H. β-Casomorphins and intestinal net fluid transport in vivo. Brantl V., Teschemacher H. β-casomorphins and related peptides recent developments . 1994;143-149 VCH, Weinheim, Germany.
8. Hautefeuille M., Brantl V., Dumontier A.M., Desjeux J.F. In vitro effects of β-casomorphins on ion transport in rabbit ileum. Am J Physiol. 250:1986;G92-G97.
9. Hunter W.M., Greenwood F.C. Preparation of iodine-131-labeled human growth hormone of high specific activity. Nature. 194:1962;495-496.
10. Koch G., Wiedemann K., Drebes E., Zimmermann W., Link G., Teschemacher H. Human β-casomorphin-8 immunoreactive material in the plasma of women during pregnancy and after delivery. Regul Pept. 20:1988;107-117.
11. Kreil G., Umbach M., Brantl V., Teschemacher H. Studies on enzymatic degradation of β-casomorphins. Life Sci. 33:(suppl I):1983;137-140.
12. Mansfeld R., Kautni J., Grunert E., Brantl V., Jöchle W. Clinical application of bovine β-casomorphins for treatment of calf diarrhea. Nyberg F., Brantl V. β-casomorphins and related peptides recent developments . 1990;105-108 Fyris-Tryck, Uppsala, Sweden.
13. Schulte-Frohlinde E., Schmid R., Brantl V., Schusdziarra V. Effect of bovine β-casomorphin-4-amide on gastrointestinal transit and pancreatic endocrine function in man. Brantl V., Teschemacher H. β-Casomorphins and related peptides recent developments . 1994;155-160 VCH Weinheim, New York.
14. Tome D., Dumontier A.M., Hautefeuille M., Desjeux J.F. Opiate activity and transepithelial passage of intact β-casomorphins in rabbit ileum. Am J Physiol. 253:1987;G737-G744.
15. Wiedemann K., Teschemacher H. Determination of β-endorphin and fragments thereof in human plasma using high-performance liquid chromatography (HPLC) and a multiple radioimmunoassay system. Pharmaceutical Res. 3:1986;142-149.